Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)

Technology appraisal
Reference number: TA674
Published: 17 February 2021

History

Invitation to participate

Final scope (PDF 88 KB)

Published:

27 October 2020
Final stakeholder list (PDF 91 KB)

Published:

27 October 2020